Tempest Therapeutics, Inc. Interest Expense Nonoperating
Tempest Therapeutics, Inc. (TPST) reported Interest Expense Nonoperating of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-13
- Tempest Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. interest expense nonoperating for fiscal 2025 was $207.00K, a 84.27% decline from fiscal 2024.
- Tempest Therapeutics, Inc. interest expense nonoperating for fiscal 2024 was $1.32M, a 9.18% decline from fiscal 2023.
- Tempest Therapeutics, Inc. interest expense nonoperating for fiscal 2023 was $1.45M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $0.00 derived: sum of 3 quarters · filed 2026-05-14 | $46.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $46.00K derived: sum of 3 quarters · filed 2026-08-13 | $207.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $46.00K derived: sum of 2 quarters · filed 2026-08-13 | $207.00K 10-Q · filed 2025-11-05 | $454.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $46.00K 10-Q · filed 2026-08-13 | $207.00K 10-Q · filed 2026-08-13 | $454.00K derived: sum of 3 quarters · filed 2026-08-13 | $783.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $161.00K 10-Q · filed 2026-05-14 | $408.00K derived: sum of 2 quarters · filed 2026-05-14 | $737.00K derived: sum of 3 quarters · filed 2026-05-14 | $1.11M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $576.00K derived: sum of 2 quarters · filed 2026-03-30 | $948.00K derived: sum of 3 quarters · filed 2026-03-30 | $1.32M 10-K · filed 2026-03-30 |
| 2024-09-30 | $329.00K 10-Q · filed 2025-11-05 | $701.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.07M 10-Q · filed 2025-11-05 | $1.45M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $372.00K 10-Q · filed 2025-08-11 | $740.00K 10-Q · filed 2025-08-11 | $1.12M derived: sum of 3 quarters · filed 2025-08-11 | $1.49M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $368.00K 10-Q · filed 2025-05-13 | $745.00K derived: sum of 2 quarters · filed 2025-05-13 | $1.12M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $377.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $750.00K derived: sum of 2 quarters · filed 2025-03-27 | $1.45M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $373.00K 10-Q · filed 2024-11-12 | $1.07M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |